NASDAQ:NOVN

Delisted

Novan . Stock News

Healthcare > Biotechnology

Buy NOVN

*Your capital is at risk

$0.0941

+0 (+0%)

At Close: Nov 20, 2023

Why Applied DNA Sciences Shares Are Trading Higher By Around 65%, Here Are 54 Stocks Moving In Monday's Mid-Day Session

03:59pm, Monday, 10'th Oct 2022 Benzinga

Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares jumped 64.5% to $2.03 after the company announced it has received its largest single purchase order for LinearDNA™ valued above the mid-six-

Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event

05:15am, Thursday, 22'nd Sep 2022 GlobeNewswire Inc.

Basel, September 22, 2022 — Novartis executives are meeting investors and industry analysts in Basel today, sharing insights into the updated company strategy at the annual Meet Novartis Management

Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent

05:00am, Wednesday, 21'st Sep 2022 GlobeNewswire Inc.

Ad hoc announcement pursuant to Art. 53 LR

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

05:15am, Monday, 19'th Sep 2022 GlobeNewswire Inc.

Basel, September 19, 2022 – Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announces further progress on its biosimilar pipeline, with the release of positive result

Novartis says authorities investigating a patent assertion

06:34am, Thursday, 15'th Sep 2022 MarketWatch

The probe into Novartis's assertion of a patent in the broader field of dermatology treatments doesn't imply wrongdoing or financial impact, the company said.

Novartis statement regarding competition authority investigation into assertion of a patent

05:30am, Thursday, 15'th Sep 2022 GlobeNewswire Inc.

Basel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss Competition Commission (COMCO) which has initiated an investigation, in collaboration with the European Co

Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials

06:30am, Saturday, 10'th Sep 2022 GlobeNewswire Inc.

Basel, September 10, 2022 — Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx® (secukinumab) demonstrated rapid and sustained relief from

Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer

05:15am, Friday, 09'th Sep 2022 GlobeNewswire Inc.

Basel, September 9, 2022 — Novartis today announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall sur

Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses

05:15am, Friday, 02'nd Sep 2022 GlobeNewswire Inc.

Basel, September 2, 2022 — Novartis today announced it will showcase data from its leading immunology portfolio and emerging pipeline at the upcoming 31st European Academy of Dermatology and Venereo

Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis

05:00am, Thursday, 01'st Sep 2022 GlobeNewswire Inc.

Basel, September 1, 2022 — Novartis today announced that James (Jay) E. Bradner, M.D., will step down from the Executive Committee of Novartis (ECN), effective October 31st after seven years leading

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by